GlassScriptPhysician profile
Akash Vasireddy
NPI 1770891590
$5,767.25
in general payments reported to CMS, 2019-2025
24 companies · $762 in 2025
The $762 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $249 · 2021: $490 · 2022: $2,769 · 2023: $427 · 2024: $454 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,643.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,467.06 | 2022 | |
| Glaxosmithkline, LLC. | $1,220.17 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $606.50 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.82 | 2019-2024 | Ofev |
| Veran Medical Technologies, INC. | $126.26 | 2019 | |
| Grifols USA, LLC | $109.29 | 2019-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $106.34 | 2020-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $99.47 | 2019-2021 | |
| United Therapeutics Corporation | $82.27 | 2021-2024 | Tyvaso |
| Pulmonx Corporation | $82.17 | 2019-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Mylan Specialty L.P. | $78.79 | 2022-2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $78.41 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.54 | 2022-2025 | Glassia |
| Insmed, INC. | $70.60 | 2019-2025 | Arikayce, Brinsupri |
| Philips North America LLC | $45.25 | 2020-2025 | Vest Therapy Und |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $40.46 | 2025 | Ohtuvayre |
| Gilead Sciences, INC. | $37.72 | 2021 | |
| Genentech USA, INC. | $33.97 | 2021 | |
| Genzyme Corporation | $33.14 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $26.43 | 2024 | Winrevair |
| Vifor Pharma, INC. | $20.75 | 2025 | Zemaira |
| Shire North American Group INC | $16.44 | 2019 | |
| Chiesi USA, INC. | $11.93 | 2021 | |
| Phathom Pharmaceuticals, INC. | $9.47 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akash Vasireddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.